Psychedelic therapy is at a crossroads. It holds immense potential to be the transformative tool we urgently need to address the limitations of existing treatments, but if we take the wrong step, it could also become just another line in medicine’s long history of almost miracles. How should we proceed? What steps can you take to ensure the future of this promising field?
The roundtable will be hosted by Angela Terhune-Hargrove, MHA, an accomplished Senior Business Development and Clinical Research Professional at Elligo Health Research® with vast professional and close personal psychedelic research experience. It will feature Kathryn LaRoe-Higgs, a renowned psychedelic psychotherapist with over a decade’s experience supporting Special Operations veterans with complex post-traumatic stress disorder (C-PTSD) and post-traumatic stress disorder (PTSD). It will also feature Dr. Kevin Murnane, Associate Professor of Pharmacology, Toxicology and Neuroscience at LSU Health Shreveport, who has active research interests in the in vivo pharmacology of psychoactive drugs and the etiology and consequences of drug misuse. The roundtable will also feature Dr. Lynnette A. Averill, Clinical Research Psychologist at the US Department of Veterans Affairs, whose focus is on studying and supporting novel, rapid-acting interventions with the potential to save lives.
We all want the millions of people living with mental illness to get the effective and comprehensive care they desperately need. Psychedelic therapy can be the solution, but only if we embrace responsible implementation, cultivate an environment of understanding and remove progress-impeding barriers.
Join the Elligo Elite Learning Series roundtable for an open discussion on shaping the future of mental healthcare with psychedelic therapy research.
(Moderator) Angela Terhune-Hargrove, MHA, Senior Business Development and Clinical Research Professional, Elligo Health Research®
Angela Terhune-Hargrove, MHA is an accomplished Senior Business Development and clinical research professional within the pharmaceutical/CRO, psychedelic research, CNS, biotech, OTC, cannabis and dietary supplements industries. She is known for fostering and leading teams that transform patient care and optimize operations.
Kathryn LaRoe-Higgs, Psychedelic Psychotherapist
Kathryn LaRoe (Katie) is a Licensed Therapist, graduating from USC with her master’s in social work with a focus on military and mental health. She is a Certified Clinical Trauma Professional II, Certified Mental Health Integrative Medicine Provider and Psychedelic Preparation/Integration Specialist. Katie unitizes integrative techniques to address the consciousness of trauma. She has worked extensively with veterans and specifically Special Operations men and women since 2008 in the plant medicine space. She enjoys a heavy focus on preparation for states of expanded consciousness, utilizing modalities that address the needs of the mind, body, soul and subtle energy.
Katie works in depth with the shadow aspects of humanity, finding grace and abundance in the lessons and teachings of their internal wisdom. Katie has worked with states of expanded consciousness for over 20 years. She has witnessed and personally experienced the healing capacity of plant medicines, breathwork, meditation and present moment focus for the mind, body, soul and energetic field. Katie has a deep appreciation for her teachers who shared their wisdom and rites of passage of yogic, Native American, Shipibo, Wixárika and Bwiti traditions. The wisdom experienced along the way has empowered her own internal healer and aided in the wisdom of navigating the various realms of the psyche for trauma resolution.
Dr. Kevin Murnane, Associate Professor of Pharmacology, Toxicology and Neuroscience, LSU Health Shreveport
Dr. Kevin Murnane has active research interests in the in vivo pharmacology of psychoactive drugs, the etiology and consequences of drug misuse, and the development of medications to treat drug misuse and comordid psychiatric and neurological disorders. In this regard, I primarily use behavior pharmacology techniques (e.g. intravenous drug self-administration, drug discrimination, reinstatement, and drug-elicited effects), behavioral neuroscience techniques (e.g. the study of sleep, cognition, and social behavior), neuropharmacology techniques (e.g. in vivo microdialysis, tissue analysis, and plasma analysis), and neuroimaging techniques (e.g. functional magnetic resonance imaging, resting state brain connectivity, magnetic resonance spectroscopy, and positron emission tomography) in laboratory animals, including mice and nonhuman primates, as well as human clinical studies. Our research is focused on cannabinoids, psychedelics, neuropeptides, and natural products.
Dr. Lynnette A. Averill, Clinical Research Psychologist, U.S. Department of Veterans Affairs
Dr. Lynnette A. Averill is the daughter of a US Marine who died by suicide after years of struggling with ineffective treatments. His life – and subsequent death – shaped Dr. Averill personally and professionally. She grew up very aware of the effects of stress and trauma, including war and combat, not only on the individual who experiences those things firsthand, but also the family, friends, and communities that experience so much in parallel. The focus of Dr. Averill’s work is on studying and supporting novel, rapid-acting interventions with potential to save lives. She is a expert in the psychoneurobiology of chronic stress pathology – namely posttraumatic stress, suicidality and rapid-acting interventions. Her research focuses on the fine-grained understanding of mechanisms underlying psychedelic medicines, the effects of chronic stress and trauma, and treatment response..
Who Should Attend?
The webinar will appeal to professionals in pharma, biotech, medical device and CROs in the following areas:
- Clinical operations
- Medical affairs
What You Will Learn
Attendees will gain insights into:
- The current state of psychedelic therapy and psychedelic therapy research, including psilocybin and its potential for treating MDD
- Essential aspects of the FDA’s new draft guidance
- Tips for optimizing psychedelic research
- Upcoming challenges in the world of psychedelic therapy research and how we can overcome them
Elligo Health Research
Elligo Health Research accelerates clinical trials through EHR data, our proprietary IntElligo® technology, and direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. Our PatientSelect® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Our SiteSelect model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.